Market Place
Sourcing Support
Cybrexa Doses First Patient In CBX-12 Phase 2 Ovarian Cancer Trial
07 Oct 2024 //
GLOBENEWSWIRE
Cybrexa Announces CBX-12 Phase 1 Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
25 Jun 2024 //
GLOBENEWSWIRE
Cybrexa Regains Rights to CBX-12
06 Feb 2024 //
GLOBENEWSWIRE
Cybrexa Therapeutics to Debut Preclinical Data Demonstrating CBX-15 is Safe
10 Oct 2023 //
GLOBENEWSWIRE
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting CBX-12
25 May 2023 //
GLOBENEWSWIRE
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
12 Apr 2023 //
GLOBENEWSWIRE
Cybrexa Strengthens Capabilities with Addition of Laurie Kenvin to the Company
01 Feb 2023 //
GLOBENEWSWIRE
Cybrexa Therapeutics Announces the Appointment of Michael N. Needle as Senior VP
15 Dec 2022 //
GLOBENEWSWIRE
Exelixis and Cybrexa Establish Exclusive Collaboration Providing Exelixis
01 Nov 2022 //
BUSINESSWIRE
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12
28 Oct 2022 //
GLOBENEWSWIRE
Cybrexa Therapeutics to Present at Upcoming Investor Conferences in June
02 Jun 2022 //
GLOBENEWSWIRE
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy
26 Oct 2021 //
GLOBENEWSWIRE
Yale spinout targets cancer`s acidic environment to boost I-O
07 Oct 2021 //
FIERCEBIOTECH
Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021
04 Aug 2021 //
PRESS RELEASE
Cybrexa Announces Publication of Peer-Reviewed Article in NAR Cancer
08 Jun 2021 //
GLOBENEWSWIRE
Cybrexa Therapeutics Appoints Stephen Basso as CFO
20 May 2021 //
GLOBENEWSWIRE
Cybrexa Announces First Patient Dosed in Phase 1/2 Clinical Trial of CBX-12
10 May 2021 //
GLOBENEWSWIRE
Cybrexa Receives Green Light from FDA on INDA for CBX-12
22 Mar 2021 //
GLOBENEWSWIRE
Cybrexa Therapeutics Closes $25 Million Series B Financing
10 Mar 2021 //
PRESS RELEASE
Cybrexa Therapeutics Enters Cooperative Research (CRADA)
24 Feb 2021 //
PRESS RELEASE
Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study
28 Jan 2021 //
GLOBENEWSWIRE
Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12
07 Jul 2020 //
GLOBENEWSWIRE
Cybrexa to Present First Efficacy and Safety Data From Its Lead Program CBX-12
14 May 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.